Director Pharmacokinetics & Bioanalysis
Tarsus Pharmaceuticals
Director Pharmacokinetics & Bioanalysis
Tarsus Pharmaceuticals
Develops FDA-approved ophthalmic therapies
About the Role
As Director, Pharmacokinetics, you'll shape the scientific and strategic direction of pharmacokinetics, drug metabolism, bioanalysis, and translational PK/PD across our entire portfolio. Working at the intersection of discovery, nonclinical development, clinical development, and regulatory strategy, you'll generate the PK insights that move programs forward — and the decisions that matter most to patients.
You'll design pharmacokinetic strategies tailored to each stage of development, lead internal and external activities, and partner closely with cross-functional teams to guide candidate selection, clinical dose planning, and regulatory submissions — turning scientific rigor into real progress for patients.
Let’s talk about how you’ll make an impact:
Driving Innovation, Inside and Out:
Factors for Success:
Minimum Requirements/Qualifications:
Preferred Qualifications:
A Few Other Details Worth Mentioning:
At Tarsus, we understand the importance of attracting and retaining top talent. The expected base pay range for this position is $188,200- $263,600 plus bonus, stock equity, and comprehensive benefits. The base pay range reflects the target range for this position, but individual pay will be determined by additional factors such as job-related skills, experience and relevant education or training. Our benefits include health, dental and vision insurance benefits to ensure your well-being. We believe in work-life balance and offer generous paid time off, including vacation, holidays, and personal days. For more details regarding Tarsus benefits, please visit: https://eb.alliant.com/26tarsusbenefitssnapshot.
#LI-Remote
Tarsus Pharmaceuticals, Inc. is an Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex including sexual orientation and gender identity, national origin, disability, protected Veteran Status, or any other characteristic protected by applicable federal, state, or local law.
Develops FDA-approved ophthalmic therapies
Tarsus Pharmaceuticals develops and markets treatments for eye care and infectious diseases, including XDEMVY (lotilaner ophthalmic solution 0.25%), an FDA-approved eye drop for Demodex Blepharitis. The product is applied as a medicated eye drop to kill Demodex mites and relieve eyelid inflammation. The company differentiates itself with a focused ocular/infectious-disease portfolio, an FDA-approved therapy, and active partnerships to expand its research and reach. Its goal is to address unmet medical needs, grow its product lineup through commercialization, and pursue new indications in eye care and infectious diseases.
Explore more opportunities at Tarsus Pharmaceuticals